Secukinumab provides faster and more sustained 52-week complete relief from psoriasis-related pain, itching, and scaling than ustekinumab in subjects with moderate-to-severe plaque psoriasis - 11/08/17
Bruce Strober, MD, University of Connecticut Health Center; Sasha Jazayeri, MD, Alliance Dermatology & Mohs; Diamant Thaci, MD, Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein; Matthias Augustin, MD, Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg; Yang Zhao, PhD, Novartis Pharmaceuticals Corporation; Isabelle Gilloteau, MS, Novartis Pharma AG; Bintu Sherif, MS, RTI Health Solutions; Vivian Herrera, DDS, Novartis Pharmaceuticals Corporation; Judit Nyirady, MD, Novartis Pharmaceuticals Corporation
Le texte complet de cet article est disponible en PDF.| Commercial support: 100% is sponsored by Novartis. |
Vol 76 - N° 6S1
P. AB229 - juin 2017 Retour au numéro
Article précédent
- Secukinumab patients with greater skin clearance response have greater improvements in skin-related quality of life and symptom relief: An analysis from the CLEAR 52-week study
- Secukinumab provides greater 52-week improvements in patient-reported outcomes versus ustekinumab in patients with moderate to severe psoriasis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?